澳大利亚类风湿关节炎患者生物制剂及靶向合成改善病情抗风湿药的使用模式
该研究基于澳大利亚风湿病学会数据库(ARAD)2003至2018年数据,描述2839例类风湿关节炎(RA)患者中生物制剂及靶向合成改善病情抗风湿药(b/tsDMARDs)的治疗模式,包括换药或停药频率及原因。研究发现换药常见,主要原因为无效或不良反应,不同b/tsDMARDs的停药风险及换药模式存在差异。
要点
- 一线b/tsDMARDs以依那西普(n=1414)和阿达木单抗(n=1024)为主。
- 一线、二线、三线治疗中分别有24.0%、31.8%、24.4%在12个月内换用另一种b/tsDMARD。
- 停药最常见原因为无效或不良反应,与治疗线数无关。
核心结论
- 在ARAD的RA参与者中,b/tsDMARDs之间的换药常见,最常见原因为无效或不良反应;暴露的持久性和换药原因因b/tsDMARD不同而异。
研究设计与样本
- 研究从澳大利亚风湿病学会数据库(ARAD)中提取2003年至2018年RA参与者换用或停用b/tsDMARDs的原因,使用桑基图和生存方法评估每种b/tsDMARD的换药模式及第一、二、三线b/tsDMARD的治疗时间,共纳入2839名参与者。
主要发现
- 一线b/tsDMARDs包括依那西普(n=1414)、阿达木单抗(n=1024)、英夫利西单抗(n=155)、戈利木单抗(n=98)、阿巴西普(n=66)、赛妥珠单抗(n=38)、托珠单抗(n=21)和托法替布(n=23)。
- 开始第一、二、三线生物制剂治疗者中,分别在12个月内换用另一种b/tsDMARD的比例为24.0%、31.8%和24.4%。
- 与一线依那西普相比,阿达木单抗(HR 1.16,95%CI:1.04,1.29)和英夫利西单抗(HR 1.77,95%CI:1.46,2.16)的停药风险更高;其他b/tsDMARDs未见差异。
- 二线治疗中,与依那西普相比,托珠单抗(HR 0.41,95%CI:0.25,0.70)、利妥昔单抗(HR 0.51,95%CI:0.30,0.85)和托法替布(HR 0.29,95%CI:0.15,0.57)的停药风险更低。
- 三线治疗中,与依那西普相比,利妥昔单抗、托珠单抗和托法替布的停药可能性也更低。
关键数值与推荐
- 与一线依那西普相比,阿达木单抗停药风险HR 1.16(95%CI:1.04,1.29),英夫利西单抗HR 1.77(95%CI:1.46,2.16)。
- 二线治疗中,与依那西普相比,托珠单抗停药风险HR 0.41(95%CI:0.25,0.70),利妥昔单抗HR 0.51(95%CI:0.30,0.85),托法替布HR 0.29(95%CI:0.15,0.57)。
- 一线、二线、三线治疗12个月内换药比例分别为24.0%、31.8%、24.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to describe treatment patterns in RA, including the frequency and reasons for switching or stopping biologic and targeted synthetic DMARDs (b/tsDMARDs). METHODS: The reasons for switching or stopping b/tsDMARDs were extracted from the Australian Rheumatology Association Database (ARAD) from 2003 to 2018 for RA participants. Switching patterns for each b/tsDMARD and time on first-, second- and third-line b/tsDMARDs were evaluated using Sankey diagrams and survival methods. RESULTS: A total of 2839 participants were included in the analysis. The first-line b/tsDMARDs were etanercept (n = 1414), adalimumab (n = 1024), infliximab (n = 155), golimumab (n = 98), abatacept (n = 66), certolizumab (n = 38), tocilizumab (n = 21) and tofacitinib (n = 23). Of those starting first-, second- and third-line biologic therapy, 24.0%, 31.8% and 24.4% switched to another b/tsDMARD within 12 months, respectively. Inefficacy or adverse effects were the most common reasons for stopping therapy, irrespective of line of treatment. Compared with first-line etanercept, participants were more likely to stop adalimumab [Hazard ratio (HR) 1.16, 95% CI: 1.04, 1.29] and infliximab (HR 1.77, 95% CI: 1.46, 2.16). No differences were seen for other b/tsDMARDs. For second-line therapies compared with etanercept, the risk of stopping was lower for tocilizumab (HR 0.41, 95% CI: 0.25, 0.70), rituximab (HR 0.51, 95% CI: 0.30, 0.85) and tofacitinib (HR 0.29, 95% CI: 0.15, 0.57). Participants taking rituximab, tocilizumab and tofacitinib were also less likely to stop third-line therapy in comparison with participants taking etanercept. CONCLUSIONS: Switching between b/tsDMARDs was common among ARAD participants with RA, most commonly due to inefficacy or adverse effects. Durability of exposure and reasons for switching varied between b/tsDMARDs.
引用
- Fletcher A, Lassere M, March L, et al. Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia. Rheumatology (Oxford). 2022. PMID: 35094044. doi:10.1093/rheumatology/keac048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。